CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia
Mené sur 90 patients atteints d'une leucémie lymphocytaire aiguë récidivante et réfractaire, cet essai évalue l'efficacité et la toxicité de l'inotuzumab, un anticorps monoclonal anti CD22
Inotuzumab ozogamicin achieves high response and molecular remission rates in patients with relapsed/refractory acute lymphoblastic leukemia with tolerable toxicity. It warrants further studies of inotuzumab in combination with chemotherapy or other targeted therapy.
Cancer , éditorial, 2012